On a corporate action affecting ordinary shares of G1 Therapeutics, Inc. (GTHX)

On August 7, 2024, G1 Therapeutics, Inc. signed a merger agreement with Pharmacosmos A/S under which Pharmacosmos A/S will acquire G1 Therapeutics, Inc. G1 Therapeutics, Inc. shareholders will receive $7.15 per share in cash per share they own. Transactions is expected to close in the third quarter of 2024. For more details, please, refer to the company’s website.

ITS Ltd. will publish separate notices on the procedures undertaken by ITS Ltd. to process this corporate action outlining how trading in these qualified investments will be carried out.